Loading cancer entity…
Loading cancer entity…
Clinical trials
10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,641)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00969462 | Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma | completed | Phase 4 | 18 | Meir Medical CenterOTHER | 1 | Jul 1, 2013 | clinicaltrials |
| NCT00926757 | Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B(HBVNHL) | completed | Phase 4 | 80 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | May 29, 2013 | clinicaltrials |
| NCT00114348 | ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia | completed | Phase 4 | 338 | Charite University, Berlin, GermanyOTHER | 1 | Feb 4, 2013 | clinicaltrials |
| NCT00162955 | Prevention of CHOP-induced Chronic Cardiotoxicity | completed | Phase 4 | 150 | Osaka City UniversityOTHER | 1 | May 8, 2012 | clinicaltrials |
| NCT00029224 | Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions | completed | Phase 4 | 500 | NovartisINDUSTRY | 1 | Feb 1, 2012 | clinicaltrials |
| NCT00652041 | Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma(TaCyDexVMP7) | completed | Phase 4 | 40 | PETHEMA FoundationOTHER | 1 | Sep 19, 2011 | clinicaltrials |
| NCT01418430 | Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) | completed | Phase 4 | — | King's College Hospital NHS TrustOTHER | 1 | Aug 22, 2011 | clinicaltrials |
| NCT00104104 | A Multiple Myeloma Trial in Patients With Bone Metastases | completed | Phase 4 | 179 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 29, 2011 | clinicaltrials |
| NCT00199017 | German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults | completed | Phase 4 | 75 | Johann Wolfgang Goethe University HospitalOTHER | 1 | Aug 23, 2010 | clinicaltrials |
| NCT01124526 | Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma | completed | Phase 4 | 75 | Asociacion Espanola de Hematologia y HemoterapiaOTHER | 1 | May 17, 2010 | clinicaltrials |
| NCT00153530 | Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) | completed | Phase 4 | 604 | Charite University, Berlin, GermanyOTHER | 1 | Dec 24, 2009 | clinicaltrials |
| NCT00466258 | LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)(LINFOTARGAM) | completed | Phase 4 | 50 | PETHEMA FoundationOTHER | 1 | Nov 25, 2009 | clinicaltrials |
| NCT00090038 | Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma | completed | Phase 4 | 168 | BiogenINDUSTRY | 11 | Oct 20, 2009 | clinicaltrials |
| NCT00415103 | AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors(AMENO-2) | completed | Phase 4 | 196 | PETHEMA FoundationOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00050999 | Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients | completed | Phase 4 | 195 | Eisai Inc.INDUSTRY | 10 | Mar 5, 2008 | clinicaltrials |
| NCT00051012 | Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients | completed | Phase 4 | 86 | Eisai Inc.INDUSTRY | 9 | Mar 5, 2008 | clinicaltrials |
| NCT00211198 | Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 4 | 60 | Eisai Inc.INDUSTRY | 1 | Mar 5, 2008 | clinicaltrials |
| NCT00257114 | Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability | completed | Phase 4 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00158041 | Subcutaneous Amifostine Safety Study | completed | Phase 4 | 452 | Mt. Sinai Medical Center, MiamiOTHER | 1 | Sep 12, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Jul 1, 2013source: clinicaltrials